Pacala Mark L
SEC CIK 1321250 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| STLN | Starling Oncology, Inc. | Dir | 286.9K | $94.2K | $200.0K | 9 | 2022-11-17 | 2026-07-27 |
Most active insiders at STLN, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Chernett Jorey | 10% | $2.69M | — |
| 2 | Hively Brad | Dir | — | $2.00M |
| 3 | Kaushal Mohit | Dir | — | $335.1K |
| 4 | Podnos Yale | Chief Medical Off | — | $276.4K |
| 5 | Pacala Mark L | Dir | — | $200.0K |
| 6 | Carter Robert Ross | CFO | — | $879.32 |
| 7 | England Kristin | Chief Administrative Off | — | — |
| 8 | Langsam Jeffrey | Chief Clinical Off | — | — |
| 9 | Ling Gabriel | Dir | — | — |
| 10 | TOI M, LLC | Dir | — | — |
Transactions 9
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-07-29 18:53 | 2026-07-27 | STLN | Starling Oncology, Inc. | Pacala Mark L | Dir | A - Grant | $0.00 | +30.1K | 286.9K | +12% | $0 | |
| M | 2025-11-24 | 2025-11-20 | STLN | Starling Oncology, Inc. | Pacala Mark L | Dir | A - Grant | $0.00 | +81.8K | 221.3K | +59% | $0 |
| M | 2025-11-20 | 2025-11-18 | STLN | Starling Oncology, Inc. | Pacala Mark L | Dir | S - Sale | $4.00 | -50.0K | 221.6K | -18% | -$200.0K |
| DI | 2025-03-28 | 2025-03-26 | STLN | Starling Oncology, Inc. | Pacala Mark L | Dir | P - Purchase | $1.04 | +90.6K | 225.0K | +67% | +$94.2K |
| 2024-11-25 | 2024-11-22 | STLN | Starling Oncology, Inc. | Pacala Mark L | Dir | A - Grant | $0.00 | +50.0K | 134.4K | +59% | $0 | |
| M | 2024-11-18 | 2024-11-12 | STLN | Starling Oncology, Inc. | Pacala Mark L | Dir | J - Other | $0.00 | -50.6K | 84.4K | -37% | $0 |
| 2023-12-28 | 2023-12-26 | STLN | Starling Oncology, Inc. | Pacala Mark L | Dir | A - Grant | $0.00 | +46.6K | 135.0K | +53% | $0 | |
| 2023-03-21 | 2023-03-17 | STLN | Starling Oncology, Inc. | Pacala Mark L | Dir | A - Grant | $0.00 | +6,562 | 88.4K | +8% | $0 | |
| M | 2022-11-21 | 2022-11-17 | STLN | Starling Oncology, Inc. | Pacala Mark L | Dir | A - Grant | $0.00 | +31.2K | 52.8K | +145% | $0 |
Purchase Sale Sale after option exercise All abbreviations